The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing “revenue of $196 million declined by 3% year-over-year” and “pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.” Additionally, the Company announced reduced financial guidance for 2025 “reflecting first quarter 2025 results and the current business outlook.”

On this news, Myriad’s stock price fell $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Myriad securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,

2121 Avenue of the Stars, Suite 800

Century City, California 90067

Call us at: 310-914-5007

Email us at: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com.

Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507909806/en/